Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries
- 作者：Baim ; Donald S. ; Cutlip ; Donald E. ; O’ ; Shaughnessy ; Charles D. ; Hermiller ; James B. ; et. al.
- 刊名：The American Journal of Cardiology
- 出版年：2001
- 期刊代码：5_00029149
- 类别：med
- 出版时间：January 15, 2001
- 卷：87
- 期：2
- 页码：152-156
- 文件大小：131 K
摘要
The NIR stent is a novel second generation tubular stent that was designed to overcome some of the limitations of the earlier Palmaz-Schatz (PS) stent design. The NIR Vascular Advanced North American (NIRVANA) trial randomized 849 patients with single coronary lesions to treatment with the NIR stent or the PS stent. The study was an “equivalency” trial, designed to demonstrate that the NIR stent was not inferior to (i.e., equivalent or better than) the PS stent, for the primary end point of target vessel failure (defined as death, myocardial infarction, or target vessel revascularization) by 9 months. Successful stent delivery was achieved in 100%versus 98.8%, respectively, with a slightly lower postprocedural diameter stenosis (7%vs. 9%, p = 0.04) after NIR and PS stent placement, respectively. Major adverse cardiac events (death, myocardial infarction, repeat target lesion revascularization) were not different at 30 days (4.3%vs. 4.4%). The primary end point of target vessel failure at 9 months was seen in 16.0%of NIR versus 17.2%of PS patients, with the NIR proving to be equal or superior to the PS stent (p <0.001 by test for equivalency). Angiographic restudy in 71%of a prespecified cohort showed no significant difference in restenosis (19.3%vs 22.4%). Thus, the NIR stent showed excellent deliverability with slightly better acute angiographic results and equivalent or better 9-month target vessel failure rate when compared with the PS stent.